A: Overall Survival from beginning of treatment (Median 6 months), B: Overall Survival from FLT3 Inhibitor treatment discontinuation (Median 3 months), C: Survival Patients Transplanted (Median 7 Months), D: Survival Patients with Undetectable Mutation After Treatment (Median 7 months), E: Survival Patients with Unchanged Mutation Status (Median 5 months), F: Survival Patients Developing Both Mutations (Median 7 months).